Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Aripiprazole 2-Month IM Depot in Schizophrenia
NCT03150771Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aripiprazole in schizophrenia (2 cohorts), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Incidence of Adverse Events, Clinical Laboratory Tests and 6 more. Started Jun 2017; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03150771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150771.